The impact of COVID-19 on cognitive and neuropathological processes leading to Parkinson’s Dementia and other Alzheimer’s Disease Related Dementias (ADRD)
Our objective is to understand potential factors, such as COVID-19, that influence the development and/or progression of Parkinson’s disease and related disorders. We will engage previous, ongoing, and future Translational Brain Research Center (TBRC) research participants to obtain information regarding exposure, current clinical and functional status, motor/cognitive daily activities, and COVID-19 history.
Participants will be asked to complete several forms, questionnaires, a motor exam, a scratch-and-sniff smell test, undergo optional neuropsychological testing, undergo optional (EMA) mobile phone remote data collection, and complete optional MRI and biosample collection. Also, a subset of subjects with and without history of COVID-19 infection will be invited for an in-person visit to obtain multimodal structural and functional MRI data, and biosamples.
Previous participation in a Translational Brain Research Center (TBRC) study, including IRB protocols 40726, 11436, 37016, 5467, 37217 and 42368.
Confirmed living through Allegra if current status is unknown by research team.
Able and willing to sign the informed consent form or has a Legally Authorized Representative (LAR) who is able and willing to do so.
Able and willing to complete the minimum required study visit questionnaires that necessitate video PSH HIPAA-Compliant Zoom (i.e., MoCA, UPSIT, MDS-UPDRS) to the best of his ability, with or without the help of a caregiver.
Unable or unwilling to complete the minimum required study visit questionnaires that necessitate video PSH HIPAA-Compliant Zoom (i.e., MoCA, UPSIT, MDS-UPDRS).
Unwillingness to complete COVID-19 History Questionnaire.
Unwillingness to complete questionnaires and assessments remotely to the best of his ability.
For those willing to undergo an optional brain MRI, any condition that precludes its routine performance.